Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jordan Shavit

Pediatric Hematology-Oncology Ann Arbor, MI Medical Doctor

NPI 1518009729 CMS profile 22492

1500 E Medical Center Dr, Ste 3, Ann Arbor, MI 48109

Open in the dashboard

General payments

$190,379

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jordan Shavit of Ann Arbor, MI is reported in the CMS Open Payments database as having received $190,379 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,752 14
2024 General $41,448 28
2023 General $35,895 23
2022 General $27,611 16
2021 General $8,749 14
2020 General $12,533 2
2019 General $30,391 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Shavit
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Jordan Shavit were reported at $33,752. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Jordan Shavit Pediatric Hematology-Oncology median Middle half National median
2019 $30,391 $184 $69–$2,094 $163
2020 $12,533 $220 $37–$3,941 $114
2021 $8,749 $366 $63–$4,909 $132
2022 $27,611 $181 $66–$2,775 $149
2023 $35,895 $175 $62–$2,600 $160
2024 $41,448 $227 $66–$2,992 $164
2025 $33,752 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $69,884 38 payments
  2. Novo Nordisk Inc $29,049 16 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $20,751 7 payments
  4. Genentech USA, Inc. $13,611 11 payments
  5. Shire North American Group Inc $12,601 26 payments
  6. BioMarin Pharmaceutical Inc. $12,280 14 payments
  7. Pfizer Inc. $12,056 8 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $7,424 13 payments
  9. Spark Therapeutics, Inc. $3,837 2 payments
  10. Medexus Pharma, Inc. $2,600 1 payment
  11. Other $6,285 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $153,459 28 payments
  2. Travel and Lodging $16,998 58 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,938 5 payments
  4. Food and Beverage $3,765 51 payments
  5. Education $207 4 payments
  6. Gift $12 4 payments
Products named General payments · program years 2019–2025
  1. ADVATE $13,774 16 payments
  2. HEMLIBRA $13,611 11 payments
  3. Roctavian $10,818 9 payments
  4. Jivi $7,424 13 payments
  5. HYMPAVZI $5,582 2 payments
  6. NO PRODUCT DISCUSSED $5,066 7 payments
  7. ELOCTATE $4,433 1 payment
  8. ADYNOVATE $3,361 3 payments
  9. IXINITY $2,600 1 payment
  10. SevenFact $2,520 7 payments
  11. Other $2,223 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record